Cardinal Health stock soars to all-time high of $155

Cardinal Health Inc (NYSE:CAH). shares have reached an unprecedented peak, touching an all-time high of $155. This milestone underscores a period of robust performance for the healthcare services company, which has seen its stock value surge over the past year. According to InvestingPro data, the company’s market capitalization now stands at approximately $37 billion, with an impressive EBITDA of $3.2 billion in the last twelve months. Investors have been buoyed by the company’s strategic initiatives and strong financial results, propelling the stock to new heights. The 1-year change data for Cardinal Health is particularly telling, with an impressive increase of 61.18%, reflecting the significant investor confidence and market momentum behind the stock. InvestingPro analysis suggests the stock remains slightly undervalued, with additional ProTips highlighting its 43-year dividend payment history and strong financial health score. This remarkable ascent to an all-time high has placed Cardinal Health in a spotlight, as market watchers and investors alike consider the company’s future prospects and the sustainability of its growth trajectory. For deeper insights into Cardinal Health’s valuation and growth potential, access the comprehensive Pro Research Report, available exclusively on InvestingPro, covering over 1,400 top US stocks.

In other recent news, Cardinal Health has reported a strong performance in its first-quarter 2025 earnings, with earnings per share (EPS) exceeding expectations at $2.35, compared to the forecast of $2.17. Although revenue slightly missed projections, coming in at $54.9 billion, the company has raised its full-year EPS guidance, reflecting a positive outlook. The pharmaceutical segment contributed significantly to this performance, with a 14% year-over-year increase in Pharmaceutical (TADAWUL:2070) Adjusted Operating Income (AOI), driven by growth in high-margin Biopharma and Managed Services Organization solutions. Additionally, Cardinal Health announced a quarterly dividend increase to $0.5107 per share, underscoring its commitment to shareholder value. In analyst updates, Citi raised its price target for Cardinal Health to $157 while maintaining a Neutral rating, noting strong performance in the pharmaceutical and other divisions despite challenges in the Global Medical (TASE:BLWV) Products Distribution segment. The company also anticipates double-digit EPS growth for fiscal year 2026, with the Pharma and Other segments expected to be major contributors. These developments highlight Cardinal Health’s strategic focus on growth and financial resilience.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.